The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
LauerS.J., CamittaB.M., LeventhalB.G.Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia: A pediatric oncology group pilot study.Cancer.1993; 71: 2854–61.
2.
BrostromB., WoodsW.G., NesbitM.E.Successful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation.J Clin Oncol.1987; 5: 376–81.
3.
LinkerC.A., LevittL.J., O'DonnellM.Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report.Blood.1991; 78(11): 2814–22.
4.
GaynonP.S., SteinherzP.G., BleyerW.A.Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.Lancet.1988; 2(8617): 921–4.
5.
BuchananG.R., RiveraG.K., PollockB.H.Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: A pediatric oncology group study.Cancer.2000; 88: 1166–74.
6.
LinkerC., DamonL., RiesC.Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.J Clin Oncol.2002; 20(10): 2464–71.
7.
ClavellL.A., GelberR.D., CohenH.J.Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.N Engl J Med.1986; 315(11): 657–63.
8.
RiveraG.K., RaimondiS.C., HancockM.L.Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy.Lancet.1993; 337: 61–6.
9.
LarsonR.A., DodgeR.K., LinkerC.A.A randomized clinical trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.Blood.1998; 92(5): 1556–64.
10.
TrisselL.A., ZhangY., CohenM.R.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection.Hosp Pharm.2001; 36(7): 740–5.
11.
PuiC.H., BoyettJ.M., HughesW.T.Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.N Engl J Med.1997; 336(25): 1781–7.
12.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
13.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
14.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 2000. Rockledge, PA: National Comprehensive Cancer Network; 2001.
15.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
HoelzerD., GokbugetN., DigelW.Outcome of adult patients with Tlymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.Blood.2002; 99(12): 4379–85.
18.
OttmannO.G., HoelzerD.Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia?Leukemia.1996; 10(7): 1111–6.
19.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18(20): 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34: 1857–64.
22.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony stimulating factors.Curr Opin Hematol.1999; 6: 145–51.
23.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.Eur J Cancer.2000; 36: S15–S21.
24.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49(9): 1796–9.
25.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
26.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–74.
27.
LowenthalR.M., EatonK.Toxicity of chemotherapy.Hematol Oncol Clin N Am.1996; 10(4): 967–90.
28.
RazisE., ArlinZ.A., AhmedT.Incidence and treatment of tumor lysis syndrome in patients with acute leukemia.Acta Haematologica.1994; 91(4): 171–4.
29.
GaynonP.S., SteinherzP.G., BleyerW.A.Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Childrens Cancer Group study CCG-106.J Clin Oncol.1993; 11(11): 2234–42.
30.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494–504.
31.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
32.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–89.
33.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 483–93.
